Abstract:Huntington's disease (HD) is an inherited progressive neurodegenerative disorder characterized by motor dysfunction and premature mortality. Luteolin, a natural flavonoid with known antioxidant and neuroprotective properties, has shown promise in various neurodegenerative diseases. This study aimed to evaluate the potential benefits of luteolin treatment in a mouse model of (HD). To assess the effects of luteolin treatment, HD N171 82Q transgenic mice received luteolin administration, while another group received a vehicle treatment for comparison. The mice's body weight changes and survival rates were monitored throughout the study. Additionally, they underwent a series of motor function tests, including the rotarod test, balance beam test, and limb clasping test. Immunohistochemical staining and western blotting were utilized to assess the localization and expression of huntingtin aggregates, respectively. Findings revealed a significant protective effect of luteolin treatment against premature mortality and prevented weight loss in HD mice compared to the non‐luteolin‐treated group. Furthermore, the luteolin‐treated mice exhibited enhanced motor coordination and balance and significantly reduced motor dysfunction‐related manifestations, such as dystonic movements. Immunohistochemistry analysis and protein quantification demonstrated a decrease in the accumulation of huntingtin aggregates in the brain's cortex, hippocampus, and striatum of luteolin‐treated mice compared to the vehicle‐treated group. These findings collectively indicate that luteolin holds promise as a therapeutic agent for managing motor dysfunction, reducing huntingtin aggregations, and improving survival outcomes in individuals affected by Huntington's disease. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression. Aims The study aimed to evaluate the potential benefits of luteolin treatment in Huntington's disease (HD), an inherited progressive neurodegenerative disorder. Methods HD N171‐82Q transgenic and WT mice received luteolin or vehicle for treatment at 6 weeks of age. The mice's body weight changes and survival rates were monitored throughout the study, and a series of motor functional tests were conducted. Serum level of the marker NfL was also determined. Immunohistochemical staining and western blotting were utilized to assess the expression of huntingtin aggregates. Results Luteolin treatment enhanced survival and prevented weight loss in HD mice compared to the vehicle‐treated HD group. Furthermore, the luteolin‐treated HD mice exhibited enhanced motor coordination and balance and significantly reduced motor dysfunction. Also, luteolin decreased serum NfL levels in HD mice. Notably, the accumulation of huntingtin aggregates was significantly reduced in the brain's cortex, hippocampus, and striatum of luteolin‐treated HD mice compared to the vehicle‐treated HD group. Conclusion Luteolin holds promise as a therapeutic agent for improving survival outcomes, managing motor dysfunction, and reducing huntingtin aggregates in HD. The findings are of significance as currently, there are no approved therapeutic interventions that reverse HD pathology or slow down its progression.

Levothyroxine attenuates behavioral impairment and improves oxidative stress and histological alteration 3-nitropropionic acid induced experimental Huntington's disease in rats

Neuroprotective effects of levothyroxine on cognition deficits and memory in an experimental model of Huntingtonʼs disease in rats: An electrophysiological study

Thyroid Hormone Supplementation Restores Cognitive Deficit, Insulin Signaling, and Neuroinflammation in the Hippocampus of a Sporadic Alzheimer's-like Disease Rat Model

The effect of L-thyroxine replacement therapy on ischemia-modified albümin and malondialdehyde levels in patients with overt and subclinical hypothyroidism

Inosine attenuates 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats via the activation of the A2AR/BDNF/TrKB/ERK/CREB signaling pathway.

N‑acetylcysteine prevents hypothyroidism‑induced impairment of learning and memory in adolescent male rats via affecting oxidative status, inflammatory response and BDNF in hippocampal tissues

Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting

Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders

Effect of Thyroid Hormone Deficiency on Oxidative Stress Parameters in Different Developing Stages of Rat Brain

Mild exercise plus levothyroxine ameliorate deficits of spatial navigation, anxiety profile, and hippocampal BDNF in hypothyroid male offspring rats

Thyroid Hormone Attenuate Nonalcoholic Fatty Liver Disease Via Inducing Autophagy In Rats

Lipid profile and levels of homocysteine and total antioxidant capacity in plasma of rats with experimental thyroid disorders

Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model

3-Nitropropionic acid induces histological and behavioral alterations in adult zebrafish: role of antioxidants on behavioral dysfunction

Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease

Levodopa Improves Behavioral Deficits of Mice with Parkinson's Disease Symptoms via Curbing NLRP3 Inflammasome Activation and Enhancing Tyrosine Hydroxylase Levels in the Striatum and Substantia Nigra.

The Effect of Experimental Thyroid Dysfunction on Markers of Oxidative Stress in Rat Pancreas

Therapeutic Effect of Levetiracetam Against Thioacetamide-Induced Hepatic Encephalopathy Through Inhibition of Oxidative Stress and Downregulation of NF-κB, NLRP3, iNOS/NO, Pro-Inflammatory Cytokines and Apoptosis

Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats

Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats